Radius Health (RDUS +6.2%) is up, albeit on below-average volume, on the heels of the launch of a Phase 3 clinical trial, wearABLe, evaluating its abaloparatide transdermal patch for the potential treatment of postmenopausal women with osteoporosis at high risk for fracture.
The primary objective is to demonstrate the patch’s non-inferiority to TYMLOS (abaloparatide) injection as measured by the percentage change in lumbar spine bone mineral density at month 12.
Enrollment should be completed by year-end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.